Simon Hohenester
Overview
Explore the profile of Simon Hohenester including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Weber S, Rek S, Eser-Valeri D, Padberg F, Reiter F, De Toni E, et al.
Visc Med
. 2021 Aug;
382:1-8.
PMID: 34373832
Introduction: Due to the coronavirus disease 19 (COVID-19) pandemic, multiple measures have been implemented including social distancing and curfews. Both the disease and measures might cause stress, particularly in persons...
12.
Hohenester S, Kanitz V, Schiergens T, Einer C, Nagel J, Wimmer R, et al.
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33202693
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and a better pathophysiologic understanding of the transition to its inflammatory phenotype (NASH) is key to the development of effective therapies....
13.
Liwinski T, Casar C, Ruehlemann M, Bang C, Sebode M, Hohenester S, et al.
Aliment Pharmacol Ther
. 2020 May;
51(12):1417-1428.
PMID: 32383181
Background: The pathogenesis of autoimmune hepatitis (AIH) is poorly understood and little is known about enteric microbiota in AIH. Aim: To investigate disease-specific microbiome alterations in AIH. Methods: The V1-V2...
14.
Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, et al.
Clin Transl Gastroenterol
. 2020 May;
11(3):e00131.
PMID: 32352707
Objectives: The precipitous increase in nonalcoholic steatohepatitis (NASH) is accompanied by a dramatic increase in the incidence of NASH-related hepatocellular carcinoma (HCC). HCC in NASH has a higher propensity to...
15.
Hohenester S, Kanitz V, Kremer A, Paulusma C, Wimmer R, Kuehn H, et al.
Cells
. 2020 Jan;
9(2).
PMID: 31979271
Hydrophobic bile salts are considered to promote liver fibrosis in cholestasis. However, evidence for this widely accepted hypothesis remains scarce. In established animal models of cholestasis, e.g., by knockout, cholestasis...
16.
Reiter F, Ye L, Bosch F, Wimmer R, Artmann R, Ziesch A, et al.
Lab Invest
. 2019 Aug;
99(12):1906-1917.
PMID: 31467426
Liver cirrhosis is a life-threatening consequence of liver fibrosis. The aim of this study was to investigate the antifibrotic potential of clinically available vitamin D analogs compared to that of...
17.
Beuers U, Hohenester S
Hepatology
. 2019 Aug;
70(5):1503-1505.
PMID: 31441502
No abstract available.
18.
Reiter F, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, et al.
Cell Oncol (Dordr)
. 2019 Jun;
42(5):705-715.
PMID: 31250364
Purpose: The cyclin-dependent kinases (CDKs) CDK4 and CDK6 are important regulators of the cell cycle and represent promising targets in cancer treatment. We aimed to investigate the relevance of CDK4/6...
19.
Canbay A, Kalsch J, Neumann U, Rau M, Hohenester S, Baba H, et al.
PLoS One
. 2019 Mar;
14(3):e0214436.
PMID: 30913263
Background & Aims: Current non-invasive scores for the assessment of severity of non-alcoholic fatty liver disease (NAFLD) and identification of patients with non-alcoholic steatohepatitis (NASH) have insufficient performance to be...
20.
Einer C, Leitzinger C, Lichtmannegger J, Eberhagen C, Rieder T, Borchard S, et al.
Cell Mol Gastroenterol Hepatol
. 2018 Dec;
7(3):571-596.
PMID: 30586623
Background & Aims: In Wilson disease, ATP7B mutations impair copper excretion into bile. Hepatic copper accumulation may induce mild to moderate chronic liver damage or even acute liver failure. Etiologic...